The poultry vaccines industry in DACH focuses on boosting health and productivity in poultry farming through scientific advancements. This sector includes biotech startups, established pharmaceutical companies, and agricultural innovators who develop vaccines to prevent diseases. As the demand for sustainable and high-quality poultry products rises, the industry is leaning toward innovative vaccine solutions tailored to emerging animal health challenges. With a push for higher biosecurity standards and enhanced animal welfare, companies are investing in research and development, aiming to provide better solutions for disease control and population management. The future looks promising, with breakthroughs poised to improve food security.


The featured investors in the DACH poultry vaccines scene represent a variety of categories, including venture capital firms and corporate investors, with headquarters in Germany and Switzerland. Established between 1932 and 2020, these investors vary in size from 11 to over 10,000 employees and have collectively engaged in numerous funding rounds, unveiling 48 total investments in 2024. This diverse group prioritizes biotechnology and agricultural innovation, reflecting a strong commitment to enhancing animal health and vaccine development in the region.


Top 7 Poultry Vaccines Investors in DACH


1. Leaps by Bayer

  • Website: leaps.bayer.com
  • Type: Venture Capital
  • Headquarters: Berlin, Berlin, Germany
  • Founded year: 2015
  • Headcount: 11-50
  • Number of deals in 2024: 16
  • LinkedIn: leapsbybayer

Leaps by Bayer is a venture capital investment firm based in Berlin, Germany, founded in 2015. It specializes in biotechnology and agriculture, aiming to support early-stage companies that are pursuing scientific breakthroughs to tackle significant global challenges in health and food security. The firm provides funding and active incubation to foster the development of innovative solutions in these sectors. Notable transactions include leading a $40 million Series B funding round for Ukko, a biotechnology startup, and participating in a $6 million Series B funding round for Amfora Inc. Additionally, they were involved in a $65 million Series C financing for AgBiome, a company focused on crop protection products, which may have implications for agricultural health, including poultry. These investments reflect Leaps by Bayer's commitment to advancing agricultural biotechnology, potentially including poultry vaccines in their future investment strategy.


2. Boehringer Ingelheim Venture Fund

  • Website: boehringer-ingelheim-venture.com
  • Type: Venture Capital
  • Headquarters: Ingelheim Am Rhein, Rhineland-Palatinate, Germany
  • Founded year: 2010
  • Headcount: 11-50
  • Number of deals in 2024: 5

Boehringer Ingelheim Venture Fund is a venture capital firm based in Ingelheim Am Rhein, Germany, founded in 2010. The fund specializes in investing in pioneering science and biotechnology innovations, particularly within the healthcare sector. They provide both capital and expertise to startups, helping them develop and commercialize their products. Notably, the fund led a USD 14 million seed financing round for Delonix Bioworks, which is working on synthetic biology vaccine platforms, showcasing their interest in vaccine development. Additionally, they have participated in various funding rounds for companies like Amal Therapeutics and Topas Therapeutics, which, while primarily focused on immuno-oncology and other therapeutic areas, reflect the fund's broader engagement in innovative healthcare solutions that could intersect with vaccine development.


3. Wellington Partners


Wellington Partners is a Munich-based venture capital firm founded in 1998, specializing in life sciences. The firm invests in early- and growth-stage companies, providing both capital and strategic support to entrepreneurs in sectors such as therapeutics and medical devices. Notably, Wellington Partners has participated in significant funding rounds for companies like MinervaX, which raised substantial amounts to advance its GBS vaccine candidate. This involvement in vaccine development highlights their commitment to supporting innovative healthcare solutions. Their investment strategy focuses on helping startups develop breakthrough technologies, which could also encompass advancements in poultry vaccines, given the firm's broad interest in life sciences.


4. Pureos Bioventures


Pureos Bioventures is a venture capital firm based in Arth, Schwyz, Switzerland, specializing in investments in innovative drug development companies, particularly in the biotechnology sector. Founded with a focus on supporting biotechnology firms, Pureos Bioventures provides both capital and strategic guidance to advance therapeutic solutions for severe diseases. In 2022, they co-led a €72M financing round for MinervaX, a Danish biotech company developing a vaccine candidate for Group B Streptococcus (GBS), which has received PRIME status from the European Medicines Agency. This investment highlights their engagement in the vaccine development space, showcasing their commitment to advancing healthcare solutions. Additionally, they have participated in various other funding rounds for companies like Memo Therapeutics, focusing on drug development, but their involvement in MinervaX is particularly relevant to the poultry vaccines context.


5. European Circular Bioeconomy Fund (ECBF)


The European Circular Bioeconomy Fund (ECBF) is a venture capital firm based in Bonn, North Rhine-Westphalia, Germany, founded in 2020. It specializes in sustainable investments aimed at fostering a circular bio-based economy. ECBF provides funding and expertise to growth-stage companies across various sectors, including agriculture, food, and industrial biotechnology. Notably, ECBF has invested in In Ovo, a Dutch AgTech company that focuses on poultry solutions, indicating their engagement in the poultry sector. In Ovo raised €34 million in a Series B funding round with ECBF's participation, highlighting their commitment to supporting innovations that could potentially include poultry vaccines. Additionally, ECBF has invested in other bioeconomy players, reinforcing their strategy to back sustainable agricultural innovations.


6. Creathor Ventures

  • Website: creathor.com
  • Type: Venture Capital
  • Headquarters: Bad Homburg, Hesse, Germany
  • Founded year: 2003
  • Headcount: 11-50
  • LinkedIn: creathor-venture

Creathor Ventures is a venture capital firm based in Bad Homburg, Hesse, Germany, founded in 2003. The firm specializes in providing funding and strategic support to startups in the technology and healthcare sectors. With a portfolio that includes companies like CEVEC Pharmaceuticals, Creathor Ventures has been active in the healthcare space for over 30 years. Notably, CEVEC Pharmaceuticals has raised multiple rounds of funding with participation from Creathor Ventures, specifically aimed at developing its proprietary CAP® Technology platform for protein and vaccine commercialization. This involvement highlights Creathor's commitment to supporting innovations in the vaccine sector, including potential applications in poultry vaccines. Additionally, their investment in Sirion Biotech, which specializes in viral vector platforms, further demonstrates their engagement in the biopharmaceutical field, which can intersect with vaccine development.


7. PHW Group


PHW Group, founded in 1932 and based in Visbek, Lower Saxony, Germany, is a corporate investor specializing in poultry production and alternative protein sources. The company offers a diverse range of poultry products and plant-based alternatives, catering to both retail and consumer markets. They emphasize sustainability and innovation in food production to meet the growing demand for healthy dietary options. Notably, PHW Group has engaged in strategic partnerships, such as with SuperMeat, an Israeli start-up focused on lab-grown 'clean chicken' products, showcasing their interest in innovative poultry solutions. Additionally, they have participated in funding rounds for companies like Kynda, Mosa Meat, and Redefine Meat, which, while primarily focused on alternative proteins, reflect their broader commitment to advancing the poultry industry and its sustainability.



Poultry Vaccines Insights: Key Investors in DACH


InvestorHeadquarterSizeFoundedDeals 2024
Leaps by BayerBerlin, Berlin, Germany11-50201516
Boehringer Ingelheim Venture FundIngelheim Am Rhein, Rhineland-Palatinate, Germany11-5020105
Wellington PartnersMunich, Bavaria, Germany11-5019989
Pureos BioventuresArth, Schwyz, Switzerland11-507
European Circular Bioeconomy Fund (ECBF)Bonn, North Rhine-Westphalia, Germany11-50202011
Creathor VenturesBad Homburg, Hesse, Germany11-5020030
PHW GroupVisbek, Lower Saxony, Germany5001-1000019321


Want to find more investors focusing on the poultry vaccines industry?

If you want to find more investors that are active in the poultry vaccinesindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and there are a lot more private equity, venturecapital, and corporate investors like these globally.

With Inven, you'll also get to know:

  • Deal History: Number of deals and their sizes.
  • Portfolio: Companies they've invested in.
  • Contact data: Key dealmakers, including their emails and phonenumbers.
  • ...and much more!